Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Current Assets: 2019-2024

Historic Current Assets for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $187.4 million.

  • Silence Therapeutics' Current Assets fell 34.70% to $133.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $639.3 million, marking a year-over-year decrease of 27.38%. This contributed to the annual value of $187.4 million for FY2024, which is 81.64% up from last year.
  • As of FY2024, Silence Therapeutics' Current Assets stood at $187.4 million, which was up 81.64% from $103.2 million recorded in FY2023.
  • Silence Therapeutics' 5-year Current Assets high stood at $187.4 million for FY2024, and its period low was $98.1 million during FY2020.
  • Moreover, its 3-year median value for Current Assets was $119.7 million (2022), whereas its average is $136.7 million.
  • As far as peak fluctuations go, Silence Therapeutics' Current Assets soared by 105.09% in 2020, and later fell by 13.80% in 2023.
  • MRY analysis of 5 years shows Silence Therapeutics' Current Assets stood at $98.1 million in 2020, then rose by 21.08% to $118.8 million in 2021, then rose by 0.74% to $119.7 million in 2022, then fell by 13.80% to $103.2 million in 2023, then skyrocketed by 81.64% to $187.4 million in 2024.
  • Its Current Assets stands at $187.4 million for FY2024, versus $103.2 million for FY2023 and $119.7 million for FY2022.